Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MBF-362 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on MBF-362, a putative EP4 (PTGER4) antagonist (Jul 2023). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MBF-362 | MBF362|MBF 362 | Limited information is currently available on MBF-362, a putative EP4 (PTGER4) antagonist (Jul 2023). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05940571 | Phase I | MBF-362 | First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors | Completed | ESP | 0 |